Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy
1Endoscopic Diagnosis and Treatment Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Abstract:
Molecular targeted therapy significantly improved the therapeutic efficacy in non-small cell lung cancer (NSCLC) patients with driver gene mutations but also with new toxicity profiles. Although most patients treated with these drugs developed relatively controllable toxicity, significant pulmonary toxicity events, including interstitial lung disease, occurred in a small proportion of patients and can lead to discontinuation or even be life-threatening. Pulmonary toxicity associated with these anti-tumor drugs is a problem that cannot be ignored in clinical practice. The prompt diagnosis of drug-related lung injury and the consequent differential diagnosis with other forms of pulmonary disease are critical in the management of pulmonary toxicity. Current knowledge of the pathophysiology and management of pulmonary toxicity associated with these targeted drugs is limited, and participants should be able to identify and respond to the development of drug-induced pulmonary toxicity. This review offers information about the potential pathogenesis, risk factors and management for the development of these events based on the available literature. This review focused on pulmonary toxicities in driver gene-positive NSCLC therapy by describing the related adverse events to promote the awareness and management of this important toxicity related to antitumor-targeted therapy.
Insights
Molecular targeted therapy for non-small cell lung cancer (NSCLC) can cause serious lung toxicity. Early diagnosis and management are crucial for patient safety and treatment continuation.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Molecular targeted therapy has improved non-small cell lung cancer (NSCLC) treatment outcomes.
- These therapies introduce unique toxicity profiles, notably pulmonary toxicity, including interstitial lung disease.
- Pulmonary toxicity can be severe, leading to treatment discontinuation or life-threatening complications.
Purpose of the Study:
- To review the pathogenesis, risk factors, and management of pulmonary toxicity associated with targeted therapies in driver gene-positive NSCLC.
- To enhance awareness and clinical response to drug-induced lung injury.
- To provide insights into managing pulmonary adverse events in NSCLC patients.
Main Methods:
- Literature review of available studies on targeted therapies for NSCLC.
- Analysis of reported pulmonary toxicities and their clinical implications.
- Synthesis of information on pathogenesis, risk factors, and management strategies.
Main Results:
- Targeted therapies for NSCLC carry a risk of significant pulmonary toxicity, such as interstitial lung disease.
- Prompt diagnosis and differential diagnosis are critical for effective management.
- Current understanding of the pathophysiology and management of these toxicities is limited but evolving.
Conclusions:
- Pulmonary toxicity is a significant, often overlooked, adverse event in targeted NSCLC therapy.
- Increased awareness and knowledge of risk factors and management are essential for clinicians.
- Further research is needed to fully elucidate the mechanisms and optimize the treatment of drug-induced lung injury.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
00:59Gene Therapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...